A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.
222261
Phase 1 other active
Quick answer
A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults. for Respiratory Syncytial Virus Infections is a Phase 1 program (other) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline Biologicals S.A.
- Indication
- Respiratory Syncytial Virus Infections
- Phase
- Phase 1
- Modality
- other
- Status
- active